Publication | Open Access

Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of the OPT-BIRISK double-blinded, placebo-controlled randomized trial

ThrombosisCardiovascular DiseaseIschemic RiskBlood PlateletCoronary Artery DiseaseHematologyClinical TrialsPharmacotherapyExtended Antiplatelet TherapyHigh BleedingAcute Myocardial InfarctionPlatelet AntagonistMedicineCardiologyEmergency MedicineAnesthesiologyHealth Sciences